Urovalve, a medical device company focused on creating superior products for urinary flow and control, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for the Company’s Surinate® Bladder Management System, allowing Urovalve to conduct a clinical study for the Company’s lead device in the United States…
More: […]
Filed under: Urology on March 31st, 2010 | No Comments »
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, announced that the Company has filed an Investigational New Drug (IND) application with the U.S…
More: continued here
Filed under: Cancer on March 31st, 2010 | No Comments »
Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced that it has completed patient enrollment in an Investigational Device Exemption (”IDE”) pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis…
More: continued here
Filed under: Clinical Trials on March 31st, 2010 | No Comments »
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan…
More: continued here
Filed under: Clinical Trials on March 31st, 2010 | No Comments »
With Thursday, April 1, 2010, marking the start of “National Donate Life Month,” Health Net, Inc. (NYSE: HNT) is working to increase awareness regarding the urgent need for organ donations - particularly among minority populations - and also to dispute some of the misperceptions surrounding organ donation. There is, however, no disputing the facts […]
Filed under: Transplants on March 31st, 2010 | No Comments »
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company’s lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC)…
More: continued here
Filed under: Cancer on March 31st, 2010 | No Comments »
Many of the more than 30,000 people a year in the United States with suspected cases of Lyme disease spirochete (bacterial) infection can now take a DNA test developed by a Connecticut scientist/physician and his team that can quickly determine if they test positive for Lyme spirochetes in their blood…
More: continued here
Filed under: Infectious Diseases / Bacteria / Viruses on March 31st, 2010 | No Comments »
SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest? Total Artificial Heart, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) clinical study of the Freedom? driver system, the first-ever U.S…
More: continued here
Filed under: Cardiovascular on March 31st, 2010 | No Comments »
In its continuing efforts to enhance patient outcomes and create efficiency in a challenging economic and regulatory climate, Advocate Physician Partners (APP), has added the power of an electronic medical record (EMR) system to its award-winning Clinical Integration (CI) Program…
More: continued here
Filed under: IT / Internet / E-mail on March 31st, 2010 | No Comments »
Weight control is one of the important topics for modern people. In addition to proper diet, regular exercise and appropriate use of medicine, obese suffers may consider weight loss surgeries for faster effects. The first successful case in NCKU Hospital reduced her weight from 118 kg to 62.8 kg one year after the surgery. Ms…
More: […]
Filed under: Obesity / Weight Loss / Fitness on March 31st, 2010 | No Comments »